Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SQ22536 (9-(tetrahydrofuran-2-yl)-9h-purin-6-amine) 是一种腺苷酸环化酶抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 185 | 现货 | ||
5 mg | ¥ 398 | 现货 | ||
10 mg | ¥ 622 | 现货 | ||
25 mg | ¥ 1,370 | 现货 | ||
50 mg | ¥ 2,370 | 现货 | ||
100 mg | ¥ 3,790 | 现货 | ||
200 mg | ¥ 4,780 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 452 | 现货 |
产品描述 | SQ22536 (9-(tetrahydrofuran-2-yl)-9h-purin-6-amine) , the adenosine analogue 9-(Tetrahydro-2-furyl)adenine, inhibited adenylate cyclase activity of crude membrane preparations from catfish (Ictalurus melas) and rat isolated hepatocytes in a non-competitive manner. |
体外活性 | SQ22536(250 μMol/L) attenuates the inhibitory effect of adenosine against ADP-induced platelet aggregation from 8±5 to 57±5%, respectively (p<0.001). SQ22536 also attenuates an increase of intraplatelet levels of cAMP by adenosine from 29±2 to 9±1 pmol/108 platelets (p<0.05). It has no effect on the platelet antiaggregant activity of inosine (1 to 4 mmol/L) and ADP-induced platelet aggregation[4]. |
体内活性 | SQ22536 abolishes the renal protective effects of liraglutide in KK/Ta-Akita mice. the amelioration of glomerular histopathological damage by liraglutide is eliminated in KK/Ta-Akita mice treated with liraglutide in combination with SQ22536. Renal cAMP does not increase after treatment with SQ22536. In a word, the beneficial actions of liraglutide for treatment of nephropathy are inhibited by the adenylate cyclase inhibitor SQ22536[5]. |
细胞实验 | HMC-1 cells and hCBMCs are plated in 48-well plates and serum-starved overnight. The next day, cells are preincubated with SQ22536 at the indicated concentrations for 30 min before stimulation with CRH (100 nM for HMC-1 or 1 μM for hCBMC) for 3 min in the presence or absence of SQ22536 in serum-free culture media. Cell lysates are then prepared and assayed for protein kinase A activity using ELISA.(Only for Reference) |
别名 | 9-(tetrahydrofuran-2-yl)-9h-purin-6-amine, SQ 22536 |
分子量 | 205.22 |
分子式 | C9H11N5O |
CAS No. | 17318-31-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10.3 mg/mL (50 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.8728 mL | 24.3641 mL | 48.7282 mL | 121.8205 mL |
5 mM | 0.9746 mL | 4.8728 mL | 9.7456 mL | 24.3641 mL | |
10 mM | 0.4873 mL | 2.4364 mL | 4.8728 mL | 12.182 mL | |
20 mM | 0.2436 mL | 1.2182 mL | 2.4364 mL | 6.091 mL | |
50 mM | 0.0975 mL | 0.4873 mL | 0.9746 mL | 2.4364 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SQ22536 17318-31-9 Neuroscience AChR 9-(tetrahydrofuran-2-yl)-9h-purin-6-amine SQ-22536 Inhibitor inhibit Adenylate Cyclase Adenylyl cyclase SQ 22536 inhibitor